(Q35994385)

11 August 2017

Aromatase inhibition: 4-hydroxyandrostenedione (4-OHA, CGP 32349) in advanced prostatic cancer (English)

1 reference

11 August 2017

1 reference

ChEBI release 2020-05-28

Davies JH

1

1 reference

11 August 2017

Dowsett M

2

1 reference

11 August 2017

Jacobs S

3

1 reference

11 August 2017

Coombes RC

4

1 reference

11 August 2017

Hedley A

5

1 reference

11 August 2017

Shearer RJ

6

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 July 1992

1 reference

British Journal of Cancer

11 August 2017

1 reference

11 August 2017

66

1 reference

11 August 2017

1

1 reference

11 August 2017

139-142

1 reference

https://scigraph.springernature.com/pub.10.1038/bjc.1992.231

11 August 2017

0 references

cites work

Aminoglutethimide: medical adrenalectomy in the management of carcinoma of the prostate. A review after 6 years

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977910

Suppression of plasma 6-keto-prostaglandin F1 alpha and 13,14-dihydro-15-keto-prostaglandin F2 alpha by aminoglutethimide in advanced breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977910

Response to aminoglutethimide and cortisone acetate in advanced prostatic cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977910

The effects of aminoglutethimide and hydrocortisone, alone and combined, on androgen levels in post-orchiectomy prostatic cancer patients

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977910

Aromatase inhibitors and benign prostatic hyperplasia

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977910

Aromatase inhibition in advanced prostatic cancer: preliminary communication.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977910

Endocrine treatment of benign prostatichypertrophy: Current concepts

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977910

The Effect of an Aromatase Inhibitor, 4-Hydroxy-4-Androstene- 3,17-Dione, On Estrogen-Dependent Processes in Reproduction and Breast Cancer11

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977910

4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977910

Antihormonal activities of 5 alpha-reductase and aromatase inhibitors.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977910

Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3,17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effects in vivo

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977910

Comparison of the pharmacokinetics and pharmacodynamics of unformulated and formulated 4-hydroxyandrostenedione taken orally by healthy men

23 September 2018

1 reference

12 December 2020

Is delayed treatment justified in carcinoma of the prostate?

1 reference

12 December 2020

Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route

1 reference

12 December 2020

1 reference

12 December 2020

Clinical and biochemical effect of aminoglutethimide in the treatment of advanced prostatic carcinoma

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1992.231

1 reference

11 August 2017

1 reference

11 August 2017

PubMed publication ID

1637664

1 reference